0000899243-20-017885.txt : 20200630
0000899243-20-017885.hdr.sgml : 20200630
20200630064741
ACCESSION NUMBER: 0000899243-20-017885
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200625
FILED AS OF DATE: 20200630
DATE AS OF CHANGE: 20200630
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'Leary James J
CENTRAL INDEX KEY: 0001449753
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39344
FILM NUMBER: 201000383
MAIL ADDRESS:
STREET 1: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02452
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fusion Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001805890
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
BUSINESS PHONE: 289-799-0891
MAIL ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-25
0
0001805890
Fusion Pharmaceuticals Inc.
FUSN
0001449753
O'Leary James J
C/O FUSION PHARMACEUTICALS INC.
270 LONGWOOD ROAD SOUTH
HAMILTON
A6
L8P 0A6
ONTARIO, CANADA
0
1
0
0
Chief Medical Officer
Stock Option (Right to Buy)
4.44
2020-03-16
4
A
0
351921
0.00
A
2030-03-16
Non-Voting Common Shares
351921
351921
D
Stock Option (Right to Buy)
17.00
2020-06-25
4
A
0
26971
0.00
A
2030-06-18
Common Shares
26971
26971
D
Stock Option (Right to Buy)
17.00
2020-06-25
4
A
0
60852
0.00
A
2030-06-25
Common Shares
60852
60852
D
25% of the shares subject to this option shall vest and become exercisable on March 16, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter. Prior to closing of the Issuer's initial public offering, such Non-Voting Common Shares will convert into Voting Common Shares and subsequently into Common Shares on a one-for-one basis.
25% of the shares subject to this option shall vest and become exercisable on June 18, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter.
25% of the shares subject to this option shall vest and become exercisable on June 25, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter.
/s/ John Crowley, Attorney-in-Fact
2020-06-29